Gilead Sciences Inc Stock Price, News & Analysis

Gilead Sciences presented new research data on its HIV treatment portfolio at HIV Glasgow 2024, including four-year outcomes from the BICSTaR study for Biktarvy®. The study demonstrated high long-term efficacy and safety, with 98% virologic suppression in treatment-naïve and 97% in treatment-experienced patients, with no treatment-emergent resistance. New data also highlighted Biktarvy's high barrier to resistance compared to other treatments. The company showcased investigational regimens with varied dosing frequencies, including once-daily, once-weekly, and twice-yearly options, focusing on person-centered drug development to address unmet needs in HIV treatment.

Gilead Sciences (GILD) has announced its executives' participation in three major investor conferences: the Jefferies London Healthcare Conference on November 20 at 9:30 AM GMT, the Piper Sandler Annual Healthcare Conference on December 3 at 11:00 AM ET, and the Annual Evercore ISI HealthCONx Conference on December 4 at 11:40 AM ET.

Live webcasts will be available on the company's investor page, with replays accessible for at least 30 days post-presentation. Gilead Sciences is a biopharmaceutical company focused on developing innovative medicines for HIV, viral hepatitis, COVID-19, and cancer, operating in over 35 countries worldwide.

Gilead Sciences announced the presentation of HIV research findings at HIV Glasgow 2024, featuring data from over 40 studies across HIV treatment and prevention. Key highlights include full results from PURPOSE 2 trial evaluating twice-yearly lenacapavir for HIV prevention, four-year outcomes from BICSTaR study demonstrating Biktarvy's efficacy and safety, and late-breaking data from a Phase 2 study on an investigational once-weekly oral combination treatment of islatravir/lenacapavir. The research spans HIV prevention, treatment options, and pipeline developments, reflecting Gilead's commitment to person-centered drug development strategies.

Gilead Sciences reported strong Q3 2024 results with total revenue increasing 7% to $7.5 billion. Product sales excluding Veklury grew 7% to $6.8 billion, driven by HIV sales up 9% to $5.1 billion. Biktarvy sales rose 13% to $3.5 billion, while Trodelvy sales increased 17% to $332 million. The company reported diluted EPS of $1.00, down from $1.73 in Q3 2023, primarily due to a $1.75 billion IPR&D impairment. Based on strong performance, Gilead raised its full-year 2024 guidance, projecting product sales of $27.8-28.1 billion and non-GAAP diluted EPS of $4.25-4.45.

Kite, a Gilead company, will present 18 studies at ASH 2024, showcasing their CAR T-cell therapy portfolio. Key highlights include positive survival outcomes from both clinical trials and real-world data. The Phase 1 study of anito-cel showed 30.2-month median progression-free survival, while the Phase 2 iMMagine-1 study demonstrated 95% objective response rate. Yescarta® continues to show superior survival rates in the largest real-world analysis for second-line therapy in large B-cell lymphoma. Long-term survival data for both Yescarta® and Tecartus® will be presented from multiple ZUMA studies across various blood cancers.

Gilead Sciences has announced a $3.15 million grant initiative supporting 22 U.S. organizations focused on providing resources and assistance to individuals affected by breast cancer. The initiative, known as the Gilead Oncology Grant, aims to promote health equity across the cancer care continuum. This funding demonstrates Gilead's commitment to transforming and simplifying care for patients with life-threatening illnesses.

Gilead Sciences is set to present over 40 abstracts at The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego. Key highlights include:

1. Primary Biliary Cholangitis (PBC): 11 abstracts, including data from the RESPONSE trial on Livdelzi® (seladelpar) efficacy and safety.

2. Hepatitis Delta Virus (HDV): Interim analysis of the Phase 3 MYR301 study on bulevirtide monotherapy.

3. Hepatitis C Virus (HCV): Safety and tolerability outcomes for Epclusa® in pregnant individuals (STORC study).

4. Hepatitis B Virus (HBV): Late-breaking data from a Phase 2a study on novel combination therapies.

5. Nonalcoholic Steatohepatitis (NASH)/Fibrosis: Validation of the Mediterranean Diet Adherence Screener for diet quality assessment.

The research spans viral and inflammatory liver diseases, reflecting Gilead's commitment to advancing liver disease treatment and care.

Gilead Sciences (GILD) and Merck (MRK) announced positive Phase 2 data for their investigational oral once-weekly combination regimen of islatravir and lenacapavir for HIV treatment. The study showed that 94.2% of participants maintained viral suppression at Week 48 after switching from daily Biktarvy to the weekly regimen. Key findings include:

- Zero participants had a viral load ≥50 copies/mL at Week 48
- Treatment-related adverse events were experienced by 19.2% of participants in the islatravir + lenacapavir group
- No grade 3 or 4 treatment-related adverse events were reported
- The combination is advancing to Phase 3 trials

This investigational regimen has the potential to become the first weekly oral HIV treatment, offering a novel option for people living with HIV.

Gilead Sciences (Nasdaq: GILD) has announced that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. The company's management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update.

A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year. Gilead Sciences is a biopharmaceutical company known for its breakthroughs in medicine, focusing on innovative treatments for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with headquarters in Foster City, California.